This website uses cookies to track and improve visitors experience - I accept your cookie policy

Sign up to receive our Newsletter

For all the latest news and views from across the angel and early-stage investment sector, plus info and discounts for our industry leading events.


14-07-2017 - - 0 comments
Lein Applied Diagnostics receives investment from Henley Business Angels

Lein Applied Diagnostics (Lein), a company developing high precision measuring technology solutions based at the Reading Enterprise Centre on the University of Reading’s Whiteknights Campus, has just closed on the first tranche of its current equity funding round. This first close saw a member of the Henley Business Angels (HBA) participate along with other angels and existing investors, raising a total of £440,000. The second close will be in the autumn of this year.

Lein is working to exploit its technology in three principal markets – diabetes care, healthcare monitoring and industrial metrology – where high precision and the ability to not contact the item under test are key requirements. Lein is already generating revenues that have grown threefold each of the last four years and at the point of achieving profitability, Lein has expectations of accelerating revenue growth from the combination of existing customers. These customers include blue chip names in the nuclear industry, as existing projects move forward and new customers launch new projects.

Perhaps of even greater interest for the long term, the money raised by Lein will be used to provide capital to exploit several new product opportunities in the medical sector that offer a significant return on investment. Lein is actively developing novel meters for the diagnosis and monitoring of both diabetes and cancer.


Dr. Dan Daly, CEO of Lein Applied Diagnostics, said: “Lein is now at a very exciting stage. The ongoing projects with existing customers are now moving into production and provide Lein with a strong financial base. In parallel, the healthcare monitoring devices that we are developing have the potential to make a large improvement to the diagnosis and care of many chronic conditions and provide Lein with the route to a significant exit valuation.”

Add a comment:




Enter the characters in the image shown:

We want your news! please send press releases to